AbbVie (ABBV) Non Operating Income (2012 - 2026)

AbbVie has disclosed Non Operating Income across 15 years of filings, most recently posting -$2.3 billion for Q1 2026.

• In Q1 2026, Non Operating Income fell 59.58% year-over-year to -$2.3 billion; the TTM figure through Mar 2026 stood at -$6.7 billion (down 62.43% YoY), while the FY2025 annual figure was -$5.8 billion, down 78.8% from the prior year.
• Non Operating Income eased to -$2.3 billion in Q1 2026, from -$1.2 billion in the prior quarter.
• Over the last five years, Non Operating Income for ABBV reached as high as $776.0 million in Q1 2022 and fell as low as -$2.6 billion in Q2 2025.
• The 5-year median for Non Operating Income is -$1.3 billion (2024), against an average of -$1.1 billion.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 1671.43% — and 2024, when it tumbled 1320.0%.
• A 5-year view of Non Operating Income shows it stood at -$2.0 billion in 2022, then increased by 23.01% to -$1.6 billion in 2023, then soared by 90.36% to -$150.0 million in 2024, then tumbled by 706.67% to -$1.2 billion in 2025, then tumbled by 90.58% to -$2.3 billion in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$2.3 billion, -$1.2 billion, and -$503.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.